

Press release

PHARMA: Italian innovation, star in Rome

Rome, 8th June 2023 – Growing Together', an event organised by NTC, an Italian pharmaceutical company with a strong international orientation, with a focus in ophthalmology and an important portfolio also in gynaecology and gastroenterology, is being held today and tomorrow in Rome. Participants are top managers of about 30 international pharmaceutical companies partnering with NTC, to discuss the present and future of Italian clinical research.

Two days of in-depth analysis and discussion in which these companies, leaders in their reference markets, will explore new therapeutic solutions born from listening to KOLs (Key Opinion Leaders), from scientific research, and from the evidence emerging from clinical practice in Italian hospitals and clinics.

"We have been working for a long time on such an ambitious project," says Riccardo Carbucicchio CEO of NTC. "Today we are opening this event and hosting some of our strategic partners to whom we are presenting a new model of collaboration between the medical profession and the company that leverages Italian creativity and professionalism."

NTC has succeeded in developing the world's first eye drops combining a fluoroquinolone antibiotic that is particularly effective in eye surgery, levofloxacin, with dexamethasone, the reference cortisone in ophthalmology. In order to demonstrate the efficacy and safety of the eye drops, NTC designed and conducted LEADER7, a phase 3, multicentre, international, randomised, parallel-group, blinded evaluator, registrational clinical trial with 800 patients undergoing cataract surgery in more than 50 centres, including 43 Italian centres.

"We are very proud to have developed, as an Italian company with the support of Italian ophthalmologists, a product that we are now exporting worldwide. We have in fact granted the rights to market it in around 90 countries. An eye drops that, by reducing antibiotic use to just one week, contributes to the containment of antibiotic resistance, an issue of great importance to NTC. Our commitment in this regard is also reflected in the valorisation of new technologies and new approaches that exploit innovative formulations also in the gynaecological and dermatological fields, such as the patented TiAB complex (based on ionic silver), useful as an adjuvant in therapeutic treatments against external microorganisms'.

The aim of this event is to showcase NTC's present and future with a view to launching new development and commercialisation projects, to make people aware of the solutions developed by NTC with the relevant scientific evidence in Ophthalmology and Gynaecology, and to strengthen the relationship with our customers in order to give them an insight into the benefits that can be derived from collaboration.

Italian research and innovation are the highlights in Rome, to support and expand new opportunities for growth and collaboration between Italy and the World.



About NTC

A pharmaceutical company headquartered in Milan - Italy, with distributors and partners in more than 100 countries, engaged in research, development, registration and commercialization of drugs, medical devices and food supplements in ophthalmology, and in other therapeutic areas including pediatrics, gynecology and gastroenterology. NTC offers to more than 200 partners innovative and high quality standard pharmaceutical products. For more information, please visit www.ntcpharma.com

Per maggiori informazioni

NTC Srl

M. Claudia Nacci

Corporate Communication

Email: claudia.nacci@ntcpharma.com

Mob: +39 3490592805